News

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...
In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...
“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...
Pedersen and Maggie Fick COPENHAGEN (Reuters) -As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the ...
(Reuters) -Telehealth company Ro has tapped tennis star Serena Williams as a celebrity patient ambassador for its weight-loss ...
As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.
Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.
Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...